PMID- 37038451
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230713
IS  - 1178-7015 (Print)
IS  - 1178-7015 (Electronic)
IS  - 1178-7015 (Linking)
VI  - 16
DP  - 2023
TI  - Efficacy and Safety of Resilient Hyaluronic Acid Fillers Injected with a Cannula: 
      A Randomized, Evaluator-Blinded, Split-Face Controlled Study.
PG  - 959-972
LID - 10.2147/CCID.S402315 [doi]
AB  - PURPOSE: Cannulas are increasingly used for injecting hyaluronic acid fillers, as 
      they are thought to improve patient comfort safety and treatment tolerability. 
      This study aimed to demonstrate the non-inferiority of a Resilient Hyaluronic 
      Acid 4 (RHA 4) filler injected with a cannula versus a needle for the treatment 
      of moderate to severe nasolabial folds (NLF). PATIENTS AND METHODS: A total of 50 
      subjects were included in a randomized, evaluator-blinded, split-face trial. The 
      NLF were injected with RHA 4 using a cannula on one side of the face and using a 
      needle on the other side on Day 0. A touch-up could be performed 4 weeks later. 
      The subjects were followed up for 12 weeks after the last injection, ie, 
      injection on Day 0 or touch-up. Efficacy was evaluated using a Wrinkle Severity 
      Rating Scale (WSRS), the Global Aesthetic Improvement Scale (GAIS), and 
      patient-reported outcomes. Safety assessments included the injection-site pain, 
      common treatment reactions (CTRs), and adverse events (AEs). RESULTS: Twelve 
      weeks after the last injection, the efficacy of the cannula treatment was found 
      to be non-inferior to that of the needle treatment, based on the WSRS score 
      improvements. The other study endpoints showed the equivalent efficacy and safety 
      of the two methods. No serious or unexpected AEs were reported. CONCLUSION: RHA 4 
      may be effectively and safely injected into the NLF using a cannula or a needle, 
      provided it is administrated by a trained practitioner.
CI  - (c) 2023 Beer et al.
FAU - Beer, Kenneth
AU  - Beer K
AD  - Beer Dermatology, West Palm Beach, FL, USA.
FAU - Biesman, Brian
AU  - Biesman B
AD  - Private Practice, Nashville, TN, USA.
FAU - Cox, Sue Ellen
AU  - Cox SE
AD  - Aesthetic Solutions, Chapel Hill, NC, USA.
FAU - Smith, Stacy
AU  - Smith S
AUID- ORCID: 0000-0002-4384-6888
AD  - California Dermatology & Clinical Research Institute, Encinitas, CA, USA.
FAU - Picault, Laura
AU  - Picault L
AD  - Teoxane Clinical Development Department, Geneve, Switzerland.
FAU - Trevidic, Patrick
AU  - Trevidic P
AD  - Expert 2 Expert, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20230406
PL  - New Zealand
TA  - Clin Cosmet Investig Dermatol
JT  - Clinical, cosmetic and investigational dermatology
JID - 101543449
EIN - Clin Cosmet Investig Dermatol. 2023 Jul 07;16:1763-1764. PMID: 37441696
PMC - PMC10082220
OTO - NOTNLM
OT  - cosmetic techniques
OT  - hyaluronic acid
OT  - injections
OT  - nasolabial fold
OT  - treatment outcome
COIS- Drs. Beer, Biesman, Cox, and Smith were clinical investigators for this study and 
      received research grants for their involvement. Mrs Picault and Dr. Trevidic have 
      financial relationship with Teoxane SA (Geneva, Switzerland) as clinical project 
      coordinator, chief scientific officer, respectively. Dr Brian Biesman reports 
      grants, personal fees from Allergan, grants, personal fees from Cytrellis, 
      grants, personal fees from ENDO, grants, personal fees from Galderma, grants, 
      personal fees from L'Oreal, personal fees from Lumenis, grants from Merz, grants, 
      personal fees from Pulse, grants, personal fees from Raziel, grants, personal 
      fees from Revance, grants, personal fees from Revision, personal fees from 
      Revelle, personal fees from RVL, grants, personal fees from Solta, grants from 
      Soliton, grants from Teoxane, grants from ZO Skin, outside the submitted work. Dr 
      Sue Ellen Cox reports research grant from Teoxane, during the conduct of the 
      study; grants, personal fees from Allergan, grants, personal fees from Galderma, 
      grants, personal fees from Croma/Hugel, outside the submitted work. Dr Stacy 
      Smith reports fair market value fees for service as medical monitor from Teoxane, 
      during the conduct of the study; medical monitor fees from Evolus, grants from 
      Sofregen, outside the submitted work. Dr Patrick Trevidic reports personal fees 
      from Teoxane, during the conduct of the study. The authors report no other 
      conflicts of interest in this work.
EDAT- 2023/04/12 06:00
MHDA- 2023/04/12 06:01
PMCR- 2023/04/06
CRDT- 2023/04/11 01:45
PHST- 2022/12/23 00:00 [received]
PHST- 2023/03/04 00:00 [accepted]
PHST- 2023/04/12 06:01 [medline]
PHST- 2023/04/11 01:45 [entrez]
PHST- 2023/04/12 06:00 [pubmed]
PHST- 2023/04/06 00:00 [pmc-release]
AID - 402315 [pii]
AID - 10.2147/CCID.S402315 [doi]
PST - epublish
SO  - Clin Cosmet Investig Dermatol. 2023 Apr 6;16:959-972. doi: 10.2147/CCID.S402315. 
      eCollection 2023.